RecruitingB-cell Non-Hodgkin Lymphoma (B-NHL)
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Eligible age
18–80 yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Sponsor: Cellectis S.A.
You may qualify if…
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- ✓ Relapsed or refractory (R/R) mature B-NHL per 2016 WHO criteria and positive for CD20 and/or CD22
- ✓ Subjects with NHL subtypes defined by WHO:
- ✓ Dose-Finding Part: R/R mature B-NHL (except chronic lymphocytic leukemia/small lymphocytic leukemia \[CLL/SLL\], Richter's transformation from prior CLL/SLL, Burkitt's lymphoma, and Waldenstrom's macroglobulinemia)
- ✓ Dose-Expansion Part: R/R LBCL, defined as:
- ✓ i. DLBCL; ii. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; iii. Transformed FL or transformed marginal zone lymphoma (MZL); iv. Follicular lymphoma Grade 3B
- ✓ R/R disease after at least 2 lines of prior treatment, which must have included:
- ✓ An Anti-CD20 MoAb and an anthracycline for DLBCL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, primary mediastinal large B-cell lymphoma (PMBCL), or transformed FL or MZL
You may not qualify if…
- ✕ Prior use of an investigational product (except for cell or gene therapies and MoAbs) within 5 half-lives or within 14 days, whichever is shorter, prior to start of LD regimen
- ✕ Previous approved therapy including chemotherapy, biologic (except MoAbs), or targeted therapy for R/R B-NHL with 5 half-lives or within 14 days, whichever is shorter, prior to start of the LD regimen
- ✕ \> 4 lines of therapy R/R B-NHL prior to start of the LD regimen.
- ✕ Prior MoAb therapy (approved or investigational) within 30 days prior to start of LD
- ✕ Prior systemic immunostimulatory agent within 3 half-lives prior to start of the LD regimen
- ✕ Prior cell or gene therapy (approved or investigational) within 6 months of the start of LD
- ✕ Prior cell or gene therapy (approved or investigational) targeting both CD20 and CD22
- ✕ Autologous HSCT infusion within 6 weeks of the start of LD
Where it's recruiting
Source: ClinicalTrials.gov · NCT05607420 · last updated 2025-08-24